On April 28, 2021 Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, reported that final results from the CANTATA clinical study will be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2021 Annual Meeting taking place virtually June 4-8, 2021 (Press release, Calithera Biosciences, APR 28, 2021, View Source [SID1234578648]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Earlier this year, Calithera announced topline results from the Phase 2 CANTATA trial, which evaluated the efficacy and safety of the company’s glutaminase inhibitor, telaglenastat, in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic renal cell carcinoma (RCC) who had been treated with one or two prior lines of systemic therapy, including immune checkpoint inhibitor or anti-angiogenic therapy. Results showed that the addition of telaglenastat to cabozantinib did not improve progression-free survival (PFS) in the study population. Additional analyses will be presented.
Following are details of the ASCO (Free ASCO Whitepaper) 2021 presentation of final CANTATA results:
Title: CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib vs. Pbo + cabozantinib in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC) that progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies
Abstract: 4501
Session Title: Genitourinary Cancer—Kidney and Bladder
Session Time: 6/7/2021 8:00am – 11:00am EDT
Presenter: Nizar M. Tannir, M.D., FACP, Professor, Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX